On February 11, 2023, Marianne De Backer, a director of Arrowhead Pharmaceuticals, Inc. (the Company), notified the Company of her decision to resign as a director, effective as of April 2, 2023. Dr. De Backeris an independent director who also serves as a member of the Company's Audit Committee, Compensation Committee, and as Chair of its Nomination Committee. Dr. De Backer's decision to resign was based on her recent appointment as Chief Executive Officer and director of Vir Biotechnology, Inc., and did not result from any disagreement with the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.95 USD | +0.75% | -7.76% | -25.00% |
05-28 | Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia | CI |
05-23 | Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.00% | 2.83B | |
+11.91% | 114B | |
+11.60% | 105B | |
-4.68% | 23.83B | |
-0.82% | 21.73B | |
-10.12% | 18.1B | |
-42.12% | 16.34B | |
-17.47% | 16.13B | |
+2.77% | 13.75B | |
+34.58% | 11.76B |
- Stock Market
- Equities
- ARWR Stock
- News Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals, Inc. Announces Resignation of Marianne De Backer, Director, Effective as of April 2, 2023